Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business of Psychedelics, Bitcoin

May 2, 2025

Psychedelics Namechecked in Trump Cabinet Meeting • Noma Therapy Raises $4.25M, Aims to Disrupt At-Home Ketamine With Insurance-Friendly Approach • Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet Christian Angermayer: Keep Politics Out of Psychedelics—And Bitcoin on the Balance Sheet • and more…

March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s Spinout

May 1, 2025

Explore or interactive database of psychedelic patent activity in March and April 2025 via our new interface. We also cover a handful of related headlines: from Lykos Therapeutics’ latest MDMA-related patent woes to a patent application-assisted peek under the hood of Seaport Therapeutics’ 2-Bromo-LSD program.

Dispatch from Breaking Convention 2025: Insights from Europe’s Largest Psychedelic Research Conference (Part 1)

April 29, 2025

The UK’s seventh biennial international conference on psychedelic consciousness welcomed researchers, clinicians and delegates to the University of Exeter from 17–19 April. In this first instalment, we dive into ketamine’s path into public healthcare, efficient and ethical trial designs, overlooked risks in the underground psychedelic scene, and whether new modalities of care can avoid repeating psychiatry’s historic mistakes.

Pα+ Psychedelic Bulletin #194: Make-or-Break Moment Looms for Compass; RFK Jr. Discusses LSD Use; Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona

April 25, 2025

Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona • Make-or-Break Moment Looms for Compass Pathways • Makary Outlines Vision for Faster Drug Approvals • RFK Jr. Details Teenage Acid Trip That Preceded Years of Addiction • Enthea Ventures into Oregon’s Psilocybin Services • A Neuroimmune Theory of Psychedelic Action? • Pilot Study Explores Psilocybin for Mood Dysfunction in Parkinson’s Disease • and more…

Psychedelic Funding Update: Q1 2025

April 22, 2025

Q1 2025 saw roughly $350M flow into the psychedelics industry, the majority of which accrued to a trio of publicly-trader drug developers. Explore key trends, private vs. public dynamics, and what Compass Pathways’ upcoming Phase 3 results could mean for the remainder of 2025.

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

April 18, 2025

Dr. Charles Raison has spent decades exploring how ancient practices like meditation, sauna, and psychedelics might interface with modern psychiatry. With roles spanning academia, clinical research, and biotech, he brings a rare perspective to the promises—and pitfalls—of emerging mental health treatments. Here, Psychedelic Alpha’s Josh Hardman sits down with Raison for a wide-ranging interview.

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more